Posted by Michael Wonder on 29 Mar 2017
FDA approves Roche’s Ocrevus (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis
29 March 2017 - First and only approved disease-modifying therapy for primary progressive form of multiple sclerosis – one of the most disabling forms of multiple sclerosis.
Roche announced today that the US FDA approved Ocrevus (ocrelizumab) as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The majority of people with MS have a relapsing form or primary progressive MS at diagnosis.
The Ocrevus marketing authorisation application has also been validated by the EMA and is currently under review.
